
Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-6529
Fax+1 614-293-9469
Dr. Monk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
OhioHealth/Riverside Methodist HospitalResidency, Internal Medicine, 1996 - 1999
Ohio State University College of MedicineClass of 1996
Certifications & Licensure
OH State Medical License 1999 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Start of enrollment: 2006 Nov 08
- Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2008 Feb 01
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Publications & Presentations
PubMed
- 9 citationsNCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.Timothy Gilligan, Daniel W Lin, Nabil Adra, Aditya Bagrodia, Darren R Feldman
Journal of the National Comprehensive Cancer Network. 2025-04-01 - Tyrosine Kinase Inhibitors Outperform Immune Checkpoint Inhibitors in Bone-Predominant Metastatic Renal Cell Carcinoma: A Multicenter Real-World Analysis.Lingbin Meng, Sarah P Psutka, Jinesh Gheeya, Mingjia Li, Meghana Noonavath
Journal of Cancer. 2025-01-01 - 12 citationsOvercoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.Adam Khorasanchi, Feng Hong, Yuanquan Yang, Eric A Singer, Peng Wang
Cancer Drug Resistance. 2025-01-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









